State Board of Administration of Florida Retirement System Reduces Stock Position in Natera, Inc. (NASDAQ:NTRA)
State Board of Administration of Florida Retirement System Reduces Stock Position in Natera, Inc. (NASDAQ:NTRA)
State Board of Administration of Florida Retirement System decreased its holdings in shares of Natera, Inc. (NASDAQ:NTRA – Get Rating) by 1.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 106,430 shares of the medical research company's stock after selling 1,246 shares during the quarter. State Board of Administration of Florida Retirement System owned about 0.11% of Natera worth $4,330,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
据佛罗里达州政府管理委员会最近提交给美国证券交易委员会(美国证券交易委员会)的文件显示,今年第一季度,该公司(纳斯达克代码:NTRA-GET Rating)的股票持有量减少了1.2%。该公司在本季度出售了1,246股后,持有这家医学研究公司106,430股股票。截至最近提交给美国证券交易委员会(Securities and Exchange Commission,美国证券交易委员会)的文件,佛罗里达州州行政委员会退休系统拥有Natera约0.11%的股份,价值4,33万美元。
Other hedge funds have also added to or reduced their stakes in the company. Commonwealth Equity Services LLC grew its holdings in shares of Natera by 6.1% during the fourth quarter. Commonwealth Equity Services LLC now owns 2,904 shares of the medical research company's stock worth $271,000 after purchasing an additional 166 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Natera by 43.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,303 shares of the medical research company's stock worth $1,056,000 after acquiring an additional 3,417 shares during the last quarter. Fifth Third Bancorp raised its holdings in shares of Natera by 6.3% during the fourth quarter. Fifth Third Bancorp now owns 5,285 shares of the medical research company's stock valued at $494,000 after acquiring an additional 313 shares in the last quarter. Duality Advisers LP purchased a new position in Natera during the 4th quarter valued at $613,000. Finally, Arizona State Retirement System lifted its position in shares of Natera by 5.4% in the 4th quarter. Arizona State Retirement System now owns 22,717 shares of the medical research company's stock worth $2,122,000 after purchasing an additional 1,157 shares during the period. Hedge funds and other institutional investors own 96.24% of the company's stock.
其他对冲基金也增持或减持了该公司的股份。去年第四季度,Federal Equity Services LLC持有的Natera股票增加了6.1%。Federal Equity Services LLC现在持有这家医疗研究公司2,904股股票,价值27.1万美元,上个季度又购买了166股。Zurcher Kantonalbank苏黎世广东银行在第四季度增持Natera股份43.3%。Zurcher Kantonalbank苏黎世广东银行现在持有这家医学研究公司11,303股股票,价值1,056,000美元,在上个季度额外购买了3,417股。Five Third Bancorp在第四季度将Natera股票的持有量增加了6.3%。Five Third Bancorp在上个季度增持了313股后,现在拥有这家医疗研究公司5285股股票,价值49.4万美元。Duality Advisers LP在第四季度购买了纳特拉的一个新头寸,价值61.3万美元。最后,亚利桑那州退休系统在第四季度将其在Natera股票的头寸提高了5.4%。亚利桑那州退休系统现在拥有22,717股这家医学研究公司的股票,价值2,122,000美元,在此期间又购买了1,157股。对冲基金和其他机构投资者持有该公司96.24%的股票。
Analysts Set New Price Targets
分析师设定新的价格目标
A number of research analysts recently issued reports on the stock. Cowen lowered their price target on shares of Natera from $110.00 to $100.00 in a research report on Friday, May 6th. Piper Sandler lowered their target price on Natera from $75.00 to $60.00 and set a "na" rating on the stock in a report on Sunday, May 15th. Robert W. Baird cut their price target on Natera from $100.00 to $71.00 in a research note on Friday, May 6th. Cowen cut their price objective on shares of Natera from $110.00 to $100.00 in a research report on Friday, May 6th. Finally, Stephens started coverage on shares of Natera in a report on Monday, April 25th. They set an "overweight" rating and a $54.00 price target on the stock. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Natera presently has an average rating of "Moderate Buy" and a consensus price target of $93.18.
一些研究分析师最近发布了关于该股的报告。考恩在5月6日星期五的一份研究报告中将纳特拉的目标股价从110.00美元下调至100.00美元。派珀·桑德勒在5月15日周日的一份报告中将其对Natera的目标价从75.00美元下调至60.00美元,并将该股的评级定为“NA”。罗伯特·W·贝尔德在5月6日星期五的一份研究报告中将纳特拉的目标价从100.00美元下调至71美元。考恩在5月6日星期五的一份研究报告中将纳特拉股票的目标价从110.00美元下调至100.00美元。最后,斯蒂芬斯在4月25日星期一的一份报告中开始报道纳特拉的股票。他们为该股设定了“增持”评级和54.00美元的目标价。一名分析师对该股的评级为卖出,六名分析师对该股的评级为买入。根据MarketBeat.com的数据,Natera目前的平均评级为“中等买入”,共识目标价为93.18美元。
Insider Activity at Natera
纳特拉的内幕活动
Natera Price Performance
纳特拉性价比
NTRA stock opened at $53.59 on Friday. The stock has a market cap of $5.20 billion, a PE ratio of -8.84 and a beta of 1.33. Natera, Inc. has a 12 month low of $26.10 and a 12 month high of $129.09. The company has a 50-day moving average price of $41.43 and a 200 day moving average price of $45.16. The company has a current ratio of 3.58, a quick ratio of 4.13 and a debt-to-equity ratio of 0.63.
NTRA股票上周五开盘报53.59美元。该股市值为52亿美元,市盈率为-8.84,贝塔系数为1.33。Natera,Inc.的12个月低点为26.1美元,12个月高位为129.09美元。该公司的50日移动均线价格为41.43美元,200日移动均线价格为45.16美元。该公司的流动比率为3.58,速动比率为4.13,债务权益比率为0.63。
Natera (NASDAQ:NTRA – Get Rating) last announced its earnings results on Thursday, August 4th. The medical research company reported ($1.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.47) by ($0.03). The business had revenue of $198.20 million for the quarter, compared to analysts' expectations of $193.67 million. Natera had a negative net margin of 79.57% and a negative return on equity of 95.97%. The firm's quarterly revenue was up 39.6% on a year-over-year basis. During the same quarter last year, the firm earned ($1.32) EPS. Equities research analysts anticipate that Natera, Inc. will post -5.75 earnings per share for the current year.
纳特拉(纳斯达克代码:NTRA-GET Rating)上一次公布财报是在8月4日星期四。这家医学研究公司公布的季度每股收益(EPS)为1.50美元,低于普遍预期的1.47美元和0.03美元。该业务当季营收为1.982亿美元,高于分析师预期的1.9367亿美元。Natera的净利润率为负79.57%,股本回报率为负95.97%。该公司季度营收同比增长39.6%。去年同期,该公司每股收益为1.32美元。股票研究分析师预计,Natera,Inc.本年度每股收益将达到5.75美元。
Natera Company Profile
纳特拉公司简介
(Get Rating)
(获取评级)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
纳特拉公司是一家诊断公司,在全球范围内开发分子检测服务并将其商业化。它提供Panorama,这是一种非侵入性产前检测,可以筛查从母亲抽血的胎儿的染色体异常,以及双胞胎的合子;Vistara,一种单基因突变筛查测试,用于识别单基因疾病;Horizon携带者筛查,以确定各种遗传疾病的携带者状态;以及Spectrum,用于在体外受精周期中识别染色体异常或遗传遗传疾病。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Natera (NTRA)
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Find and Profitably Trade Stocks at 52-Week Lows
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
- 免费获取StockNews.com关于Natera(NTRA)的研究报告
- 霍尼韦尔看好稳定和多元化的股票
- 为什么要投资高收益股利股票?
- 迪士尼(NYSE:DIS)的股票刚刚给了投资者一个巨大的信号
- 找到并获利于52周低点的股票交易
- 清洁能源法案通过后,太阳能股大放异彩
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
接受《纳特拉日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Natera和相关公司的最新新闻和分析师评级的每日简要摘要。